54. (currently amended) An adenovirus vector comprising an adenoviral gene essential for replication under transcriptional control of a uroplakin II (UPII) transcriptional response element (TRE) comprising a nucleotide sequence selected from the group consisting of nucleotides 2028 to 2239 of SEQ ID NO:1; nucleotides 1647 to 2239 of SEQ ID NO:1; nucleotides 1223 to 2239 of SEQ ID NO:1; nucleotides 1 to 2239 of SEQ ID NO:1; nucleotides 430 to 2239 of SEQ ID NO:1; nucleotides 2023-2239 of ~~SEQ ID NO:2~~ SEQ ID NO:1; nucleotides 3005 to 3592 of SEQ ID NO:2; and 2627 to 3592 of SEQ ID NO:2.

55. (canceled)

56. (previously presented) An adenovirus vector according to claim 54, wherein the adenoviral gene essential for replication is an adenoviral early gene.

57. (canceled)

58. (previously presented) An adenovirus vector according to claim 56, wherein the adenoviral early gene is E1A.

59. (previously presented) An adenovirus vector according to claim 56, wherein the adenoviral early gene is E1B.

60. (original) The adenovirus vector of claim 59, wherein E1B has a deletion of the 19-kDa region.

61. (previously presented) An adenovirus vector according to claim 54, wherein the adenoviral gene essential for replication is an adenoviral late gene.

62. (cancelled)

63. (previously presented) An adenovirus vector according to claim 54, wherein the uroplakin gene TRE is obtained from a mouse uroplakin II gene.

64. (previously presented) An adenovirus vector according to claim 63, wherein the TRE comprises nucleotides 3005-3592 of SEQ ID NO:2.

65. (previously presented) An adenovirus vector according to claim 54, wherein said TRE comprises nucleotides 2627-3592 of SEQ ID NO:2.

66. (previously presented) An adenovirus vector according to claim 54, wherein the uroplakin II TRE is obtained from a human uroplakin II gene.

67. (previously presented) An adenovirus vector according to claim 54, wherein said TRE comprises nucleotides 1-2239 of SEQ ID NO:1.

68. (previously presented) An adenovirus vector according to claim 54, wherein said TRE comprises nucleotides 2023-2239 of SEQ ID NO:2.

69. (previously presented) An adenovirus vector according to claim 54, wherein said TRE comprises nucleotides 430-2239 of SEQ ID NO:1.

70. (previously presented) An adenovirus vector comprising

(a) an adenovirus gene essential for replication under transcriptional control of a uroplakin II transcriptional regulatory element (TRE) comprising a nucleotide sequence selected from the group consisting of nucleotides 2028 to 2239 of SEQ ID NO:1; nucleotides 1647 to 2239 of SEQ ID NO:1; nucleotides 1223 to 2239 of SEQ ID NO:1; nucleotides 1 to 2239 of SEQ ID NO:1; nucleotides 430 to 2239 of SEQ ID NO:1; nucleotides 2023-2239 of SEQ ID NO:2; nucleotides 3005 to 3592 of SEQ ID NO:2; and 2627 to 3592 of SEQ ID NO:2; and

(b) an E3 region.

71-77. (canceled)

78. (previously presented) The adenovirus vector according to claim 70, wherein the uroplakin II TRE is obtained from a mouse uroplakin II gene.

79. (previously presented) The adenovirus vector according to claim 70, wherein the uroplakin II TRE is from a human uroplakin II gene.

80-81. (canceled)

82. (previously presented) An *in vitro* host cell comprising the adenoviral vector of claim 54.

83. (previously presented) An *in vitro* host cell comprising the adenoviral vector of claim 70.

84-103. (canceled)

104. (previously presented) The adenovirus vector of claim 54, further comprising a polynucleotide encoding adenoviral death protein (ADP).

105. (previously presented) The adenovirus vector of claim 70, further comprising a polynucleotide encoding adenoviral death protein (ADP).

106. (previously presented) The adenovirus vector of claim 54, further comprising a GM-CSF gene.

107. (previously presented) The adenovirus vector of claim 70, further comprising a GM-CSF gene.